Tag
This review analyzes the STABLED trial findings alongside major AFib rhythm control studies, evaluating the efficacy and safety of catheter ablation added to DOAC therapy for secondary stroke prevention.
The STABLED randomized clinical trial found that adding catheter ablation to standard edoxaban therapy did not significantly reduce the risk of recurrent stroke or composite cardiovascular outcomes in patients with atrial fibrillation and a
A hierarchical win ratio analysis of the NOAH-AFNET 6 trial confirms that edoxaban does not provide a net clinical benefit over no anticoagulation in patients with device-detected atrial fibrillation, primarily due to the balance between lo
The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor id
The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic ev
